ARL6IP6 Proteins, cDNA Clones Research Reagents

All ARL6IP6 reagents are produced in house and quality controlled, including 26 ARL6IP6 Gene, 1 ARL6IP6 Lysate, 1 ARL6IP6 Protein, 2 ARL6IP6 qPCR. All ARL6IP6 reagents are ready to use.

ARL6IP6 Protein (1)

    ARL6IP6 cDNA Clone (26)


    クローニングベクター cDNA 製品

    In lentiviral vector


    クローニングベクター cDNA 製品

    In lentiviral vector

    ARL6IP6 Lysate (1)

      ARL6IP6 の背景知識

      It had been found that a homozygous truncating mutation in ARL6IP6 as the likely cause of a syndromic form of CMTC associated with major dysmorphism, developmental delay, transient ischemic attacks and cerebral vascular malformations. This gene was previously implicated by genome wide association study (GWAS) as a susceptibility locus to ischemic stroke in young adults. We identify ARL6IP6 as a novel candidate gene for a syndromic form of CMTC. This suggests that ischemic stroke or transient ischemic attacks (TIA) may represent, at least in some cases, the mild end of a phenotypic spectrum that has at its severe end autosomal recessive CMTC. This finding contributes to a growing appreciation of the continuum of Mendelian and common complex diseases.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.